Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
1.
J Neurooncol ; 62(3): 329-38, 2003 May.
Article in English | MEDLINE | ID: mdl-12777086

ABSTRACT

BACKGROUND: The signal of choline containing compounds (Cho) in proton magnetic resonance spectroscopy (1H-MRS) is elevated in brain tumors. [11C]choline uptake as assessed using positron emission tomography (PET) has also been suggested to be higher in brain tumors than in the normal brain. We examined whether quantitative analysis of choline accumulation and content using these two novel techniques would be helpful in non-invasive, preoperative evaluation of suspected brain tumors and tumor malignancy grade. METHODS: 12 patients with suspected brain tumor were studied using [11C]choline PET, gadolinium enhanced 3-D magnetic resonance imaging and 1H-MRS prior to diagnostic biopsy or resection. Eleven normal subjects served as control subjects for 1H-MRS. RESULTS: The concentrations of Cho and myoinositol (mI) were higher and the concentration of N-acetyl signal/group (NA) lower in brain tumors than in the corresponding regions of the normal brain. There were no significant differences in metabolite concentrations between low- and high-grade gliomas. In non-tumorous lesions Cho concentrations were lower and NA concentrations higher than in any of the gliomas. Enormously increased lipid peak differentiated lymphomas from all other lesions. The uptake of [11C]choline at PET did not differ between low- and high-grade gliomas. The association between Cho concentration determined in 1H-MRS and [11C]choline uptake measured with PET was not significant. CONCLUSION: Both 1H-MRS and [11C]choline PET can be used to estimate proliferative activity of human brain tumors. These methods seem to be helpful in differential diagnosis between lymphomas, non-tumorous lesions and gliomas but are not superior to histopathological methods in estimation of tumor malignancy grade.


Subject(s)
Astrocytoma/diagnostic imaging , Brain Neoplasms/diagnostic imaging , Carbon Radioisotopes , Choline , Lymphoma/diagnostic imaging , Adult , Aged , Astrocytoma/diagnosis , Brain Neoplasms/diagnosis , Choline/analogs & derivatives , Contrast Media , Female , Humans , Lymphoma/diagnosis , Magnetic Resonance Imaging , Male , Middle Aged , Tomography, Emission-Computed
2.
Nucl Med Biol ; 28(7): 857-63, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11578908

ABSTRACT

The present study describes the synthesis of the [18F]fluoromethyl analogue of (+)-McN5652 ([18F]FMe-McN) as a new potential tracer for the serotonin transporter. In vitro binding studies have shown that FMe-McN displays only slightly lower affinity for the serotonin transporter (K(i) = 2.3 +/- 0.1 nM) than (+)-McN5652 (K(i) = 0.72 +/- 0.2 nM). The radiofluorinated tracer [18F]FMe-McN was prepared by reaction of normethyl (+)-McN5652 with the fluoromethylation agent [18F]bromofluoromethane in an overall radiochemical yield of 5 +/- 1% (decay-corrected, related to [18F]fluoride) and with high specific radioactivity (200-2,000 GBq/micromol at the end of synthesis).


Subject(s)
Carrier Proteins/metabolism , Isoquinolines/chemical synthesis , Membrane Glycoproteins/metabolism , Membrane Transport Proteins , Nerve Tissue Proteins , Radiopharmaceuticals/chemical synthesis , Serotonin Antagonists/chemical synthesis , Animals , Caudate Nucleus/metabolism , Drug Stability , Fluorine Radioisotopes , In Vitro Techniques , Indicators and Reagents , Isotope Labeling , Magnetic Resonance Spectroscopy , Paroxetine/metabolism , Radioligand Assay , Radiopharmaceuticals/pharmacology , Serotonin Plasma Membrane Transport Proteins , Selective Serotonin Reuptake Inhibitors/metabolism , Solvents , Swine , Tomography, Emission-Computed
3.
Eur J Nucl Med ; 28(7): 847-54, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11504081

ABSTRACT

[N-methyl-11C]alpha-Methylaminoisobutyric acid (11C-MeAIB) is a potentially useful tracer for positron emission tomography (PET) studies on hormonally regulated system A amino acid transport. 11C-MeAIB is a metabolically stable amino acid analogue specific for system A amino acid transport. We evaluated the biodistribution of 11C-MeAIB in rats and humans to estimate the usefulness of the tracer for in vivo human PET studies, for example, on regulation of system A amino acid transport and on tumour imaging. Healthy Sprague-Dawley rats (n=14) were killed 5, 20, 40 or 60 min after the injection of 11C-MeAIB, and the tissue samples were weighed and counted for 11C radioactivity. Ten lymphoma patients with relatively limited tumour burden underwent whole-body (WB) PET imaging with 11C-MeAIB. In addition, three other patients had dynamic PET scanning of the head and neck area, and the tracer uptake was quantitated by calculating the kinetic influx constants (Ki values) for the tracer. In animal studies, the highest activity was detected in the kidney, pancreas, adrenal gland and intestines. In humans, the highest activity was found in the salivary glands, and after that in the kidney and pancreas, similar to the results in animal studies. Rapid uptake was also detected in the skeletal muscle. In the graphical analysis, linear plots were obtained, and the mean fractional tracer uptake values (Ki) of the parotid glands (n=3) and cervical muscles (n=3) were 0.039+/-0.008 min(-1) and 0.013+/-0.006 min(-1), respectively. The Ki value of the tumour (n=1) was 0.064 min(-1). Higher uptake of 11C-MeAIB into the tumour tissue was encountered. These results encourage further 11C-MeAIB PET studies in humans on the physiology and pathology of system A amino acid transport and on tumour detection.


Subject(s)
Amino Acid Transport System A/analysis , Carbon Radioisotopes/pharmacokinetics , Tomography, Emission-Computed , beta-Alanine/analogs & derivatives , beta-Alanine/pharmacokinetics , Adult , Aged , Animals , Female , Humans , Lymphoma/diagnostic imaging , Lymphoma/metabolism , Male , Middle Aged , Rats , Rats, Sprague-Dawley , Tissue Distribution
4.
Eur J Nucl Med ; 28(3): 334-9, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11315601

ABSTRACT

Carbon-11 acetate positron emission tomography (PET) has been widely used to assess regional oxidative metabolism of the heart. However, the accuracy of [11C]acetate PET in assessing oxidative metabolism in infarcted myocardium remains controversial. Thirteen patients with stable coronary artery disease and old myocardial infarction were studied. The 15O-based PET studies yielded regional blood flow (rMBF, ml/min/g) and oxygen consumption (rMMRO2, ml/min/g), which was compared with the myocardial clearance rate constant (kmono) of [11C]acetate in segments with rMBF > or = 75% (group A), 50%-74% (group B) or < 50% (group C) of the normal reference segment. Mean MBF was 0.96 +/- 0.08 ml/g/min in group A, 0.67 +/- 0.06 ml/g/min in group B and 0.42 +/- 0.07 ml/g/min in group C segments. The segmental rMMRO2 correlated linearly with kmono (r = 0.89, P < 0.001, y = 0.61x + 0.026). The kmono/rMMRO2 ratio was comparable in the group A and B segments (0.99 +/- 0.19 vs 1.07 +/- 0.21, P = NS). However, the ratio was significantly higher in the group C segments (1.28 +/- 0.35, P = 0.037). It is concluded that kmono of [11C]acetate correlates linearly with rMMRO2 determined by [15O]O2 inhalation. However, kmono appears to yield higher rMMRO2 estimates than the [15O]O2 method in low-flow areas.


Subject(s)
Acetates , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/metabolism , Myocardium/metabolism , Oxygen Consumption/physiology , Radiopharmaceuticals , Aged , Carbon Radioisotopes , Chronic Disease , Coronary Circulation , Female , Hemodynamics/physiology , Humans , Male , Middle Aged , Oxygen Radioisotopes , Tomography, Emission-Computed
5.
Eur J Nucl Med ; 28(3): 373-6, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11315607

ABSTRACT

Abnormalities of the autonomic nervous system are known to be of prognostic significance in chronic heart failure (CHF). The prognostic value of positron emission tomography (PET) imaging of cardiac autonomic innervation in CHF has not been explored previously. We retrospectively studied the survival data of 46 NYHA class II-III CHF patients (mean LVEF 35% +/- 8%) who had undergone carbon-11 hydroxyephedrine (11C-HED) studies at the Turku PET Centre between August 1992 and March 1996. The origin of CHF was dilated cardiomyopathy in 13 of the 46 patients and coronary artery disease with at least one prior myocardial infarction in the remaining 33. Data on causes of death and heart transplantation were collected, and the statistically significant predictors of prognosis were analysed using Cox's proportional hazards regression. During the mean follow-up period of 55 +/- 19 months, 11 deaths occurred and two patients underwent heart transplantation successfully. Eleven end-points were classified as cardiac (nine sudden cardiac deaths and two deaths due to progressive heart failure) and two as non-cardiac. When divided into two groups based on the median of 11C-HED retention (mean 0.184 +/- 0.061, median 0.183), eight end-points (death or cardiac transplantation) were reached in the group with 11C-HED retention below the median and three in the group with 11C-HED retention above the median (P < 0.02). In proportional hazards regression analysis, only peak oxygen uptake (peak VO2), left ventricular end-diastolic volume and HED retention were found to be statistically significant. It is concluded that 11C-HED PET provides independent prognostic information in patients with CHF.


Subject(s)
Ephedrine/analogs & derivatives , Ephedrine/pharmacokinetics , Heart Failure/diagnostic imaging , Heart/diagnostic imaging , Myocardium/metabolism , Radiopharmaceuticals/pharmacokinetics , Aged , Carbon Radioisotopes , Chronic Disease , Echocardiography , Female , Follow-Up Studies , Humans , Male , Middle Aged , Odds Ratio , Prognosis , Survival Analysis , Tomography, Emission-Computed
6.
Appl Radiat Isot ; 54(6): 927-33, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11300406

ABSTRACT

[18F]Bromofluoromethane was synthesised from dibromomethane by substitution of bromine with [18F]fluoride. The synthesis and separation of the [18F]bromofluoromethane were automated. [18F]Bromofluoromethane was used to convert a phenolic and a thiophenolic precursor into a labelled ether and thioether, respectively. The specific radioactivity of these labelled products was determined with both high-performance liquid chromatography (with UV-absorbance detection) and liquid chromatography (with mass spectrometric detection). The median for the specific radioactivity, corrected at the end of radionuclide production, was 934GBq/micromol (range 40-9900 GBq/micromol; n = 83).


Subject(s)
Fluorine Radioisotopes , Hydrocarbons, Brominated/chemical synthesis , Hydrocarbons, Fluorinated/chemical synthesis , Automation/instrumentation , Automation/methods , Chromatography, High Pressure Liquid , Cyclotrons , Indicators and Reagents , Mass Spectrometry
7.
Clin Pharmacol Ther ; 68(5): 522-31, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11103755

ABSTRACT

AIMS: Levosimendan, a novel calcium-dependent calcium sensitizer of the myocardial contractile proteins, also enhances diastolic relaxation and induces peripheral vasodilation by opening potassium channels. To assess the combined energetical effects of levosimendan infusion in vivo, we performed positron emission tomography in patients with decompensated chronic heart failure. METHODS AND RESULTS: Eight hospitalized patients with New York Heart Association functional class III or IV heart failure received levosimendan or placebo intravenously in a randomized double-blind cross-over study. During steady-state, dynamic positron emission tomography with [11C]acetate was used to assess myocardial oxygen consumption and [15O]H2O to measure myocardial blood flow. Cardiac performance and dimensions were assessed by pulmonary artery catheterization and echocardiography. Compared with healthy volunteers, myocardial oxygen consumption during placebo was elevated in the right ventricle but comparable in the left ventricle. During administration of levosimendan, cardiac output increased by 32% (P = .002) mainly because of higher stroke volume. Coronary, pulmonary, and systemic vascular resistance values were significantly reduced. Mean myocardial blood flow increased from 0.76 to 1.02 mL/min/g (P = .033). Levosimendan was neutral on myocardial oxygen consumption and left ventricular efficiency, but it improved right ventricular mechanical efficiency by 24% (P = .012). CONCLUSIONS: Levosimendan has an energetically favorable short-term profile in the treatment of congestive heart failure. It enhances cardiac output without oxygen wasting, particularly by improving efficiency in the right ventricle.


Subject(s)
Cardiotonic Agents/therapeutic use , Heart Failure/drug therapy , Hemodynamics/drug effects , Hydrazones/therapeutic use , Pyridazines/therapeutic use , Cardiotonic Agents/administration & dosage , Catheterization, Swan-Ganz , Coronary Vessels/drug effects , Cross-Over Studies , Double-Blind Method , Female , Heart Failure/diagnostic imaging , Humans , Hydrazones/administration & dosage , Infusions, Intravenous , Male , Middle Aged , Oxygen Consumption/drug effects , Pyridazines/administration & dosage , Simendan , Tomography, Emission-Computed , Ultrasonography
8.
Int J Radiat Oncol Biol Phys ; 48(1): 43-52, 2000 Aug 01.
Article in English | MEDLINE | ID: mdl-10924970

ABSTRACT

PURPOSE: To evaluate the feasibility of [(11)C]-methionine positron emission tomography (MET PET) in radiotherapy (RT) treatment planning and long-term follow-up in patients with low-grade glioma. PATIENTS: Thirteen patients with low-grade astrocytoma and 1 with anaplastic astrocytoma underwent sequential MET PET and magnetic resonance imaging (MRI) before and 3, 6, 12, and 21-39 months after RT, respectively. Ten patients were studied after initial debulking surgery or biopsy and 4 in the recurrence phase. METHODS: A total of 58 PET scans were performed. After transmission scanning, a median dose of 425 MBq of MET was injected intravenously and emission data was acquired 20 min after injection for 20 min. The uptake of MET in tumor area was measured as standardized uptake value (SUV) and tumor-to-contralateral brain SUV ratios were generated to assess irradiation effects on tumor metabolism. Functional imaging with PET was compared with concurrent MRI in designing the RT planning volumes and in assessment of response to RT during a median follow-up time of 33 months. RESULTS: In 12 patients (86%), tumor area was clearly discernible in the baseline PET study. In the remaining 2 patients with a suspected residual tumor in MRI, PET showed only a diffuse uptake of MET interpreted as negative in the original tumor area. In the dose planning of RT, MET PET was helpful in outlining the gross tumor volume in 3 of 11 cases (27%), whereas PET findings either coincided with MRI (46%) or were less distinctive (27%) in other cases. In quantitative evaluation, patients with a low tumor SUV initially had significantly better prognosis than those with a high SUV. Tumor-to-contralateral brain uptake ratios of MET discriminated well patients remaining clinically stable from those who have since relapsed or died of disease. CONCLUSION: Quantitative MET PET has prognostic value at the time of initial treatment planning of low-grade glioma. Some patients may benefit of RT volume definition with MET PET, which seems to disclose residual tumor better than MRI in selected cases. Stable or decreasing uptake of MET in tumor area after RT during follow-up seems to be a favorable sign.


Subject(s)
Astrocytoma/diagnostic imaging , Brain Neoplasms/diagnostic imaging , Carbon Radioisotopes , Methionine , Radiotherapy Planning, Computer-Assisted/methods , Tomography, Emission-Computed/methods , Adult , Astrocytoma/metabolism , Astrocytoma/radiotherapy , Brain Neoplasms/metabolism , Brain Neoplasms/radiotherapy , Feasibility Studies , Female , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Male , Methionine/pharmacokinetics , Middle Aged , Radiotherapy Dosage
9.
Neurology ; 54(12): 2252-60, 2000 Jun 27.
Article in English | MEDLINE | ID: mdl-10881249

ABSTRACT

OBJECTIVE: To detect reduced [11C]flumazenil in patients with temporal lobe epilepsy (TLE) and to relate binding to histopathology. METHODS: The authors studied 16 patients who underwent epilepsy surgery because of drug-resistant TLE using [11C]flumazenil PET and quantitative MRI. In 12 patients, resected hippocampus was available for histologic analysis. [11C]Flumazenil binding potential (fitted BP) was assessed with the simplified reference tissue model. RESULTS: [11C]Flumazenil fitted BP in the medial temporal lobe was reduced in all patients with abnormal hippocampal volumetry or T2 relaxometry on MRI. Fitted BP was also reduced in 46% of the patients with hippocampal volume within the normal range and in 38% of patients with less than 2 SD T2 prolongation. In all MRI-negative/PET-positive patients, the histologic analysis verified hippocampal damage. Also, [11C]flumazenil fitted BP correlated with the severity of reduced hippocampal volume, T2 prolongation, and histologically assessed neuronal loss and astrogliosis. CONCLUSION: [11C]Flumazenil PET provides a useful tool for investigating the hippocampal damage in vivo even in patients with no remarkable hippocampal abnormalities on quantitative MRI.


Subject(s)
Epilepsy, Temporal Lobe/diagnostic imaging , Flumazenil/pharmacokinetics , Hippocampus/metabolism , Temporal Lobe/metabolism , Adolescent , Adult , Anticonvulsants/therapeutic use , Benzodiazepines/therapeutic use , Epilepsy, Temporal Lobe/diagnosis , Epilepsy, Temporal Lobe/therapy , Female , GABA Modulators/pharmacokinetics , Hippocampus/diagnostic imaging , Hippocampus/pathology , Hippocampus/surgery , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Temporal Lobe/diagnostic imaging , Temporal Lobe/pathology , Tomography, Emission-Computed , Treatment Outcome , Valproic Acid/therapeutic use , Vigabatrin/therapeutic use
10.
Eur J Nucl Med ; 27(1): 25-32, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10654143

ABSTRACT

[methyl-11C]choline (11C-choline) is a radioligand potentially useful for oncological positron emission tomography (PET). As a first step towards the development of a kinetic model for quantification of 11C-choline uptake, blood metabolism of 11C-choline during PET imaging was studied in humans. High-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC) were used for the analysis of 11C-choline and its radioactive metabolites. Prior to human PET imaging we studied ex vivo the biodistribution and metabolism of intravenously administered 11C-choline in rats. Our results revealed that the radioactivity accumulated particularly in kidney, lung, adrenal gland and liver. Chromatographic analysis showed that the level of unmetabolized 11C-choline in rat plasma decreased from 42% +/- 20% (mean +/- SD) at 5 min to 21% +/- 10% at 15 min after injection. In accordance with these findings, in humans the unmetabolized 11C-choline represents 62% +/- 19% of the total radioactivity in arterial plasma at 5 min after injection and 27% +/- 12% at 15 min. In human venous plasma the corresponding values were 85% +/- 12% and 48% +/- 12% at 5 and 10 min, respectively. The major metabolite observed in both human and rat plasma was identified as 11C-betaine. In human arterial plasma this maximally represented 82% +/- 9% of the total radioactivity at 25 min after radiotracer injection. By 20 min after injection, the 11C-choline and 11C-betaine in human arterial plasma reached a plateau, and their fractional activities remained nearly constant thereafter. Although most of the circulating 11C-choline in blood is transported to tissues, it does not disappear totally from blood within the first 40 min after tracer injection.


Subject(s)
Carbon Radioisotopes , Choline/analogs & derivatives , Tomography, Emission-Computed , Animals , Betaine/blood , Choline/blood , Chromatography, High Pressure Liquid , Chromatography, Thin Layer , Humans , Rats , Rats, Sprague-Dawley , Time Factors , Tissue Distribution
11.
J Nucl Med ; 41(1): 65-70, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10647606

ABSTRACT

UNLABELLED: Dopamine D2 receptor function was assessed in a PET study with 2 dopamine D2 receptor PET ligands, [11C]raclopride (RAC) and [11C]N-methylspiperone (NMSP), in early Parkinson's disease. METHODS: Seven patients with early Parkinson's disease and 5 healthy volunteers were studied. Each underwent PET both with reversible [11C]RAC and with irreversible [11C]NMSP. RESULTS: Upregulation of dopamine D2 receptors in the putamen contralateral to the predominant symptoms of Parkinson's disease was confirmed using both [11C]RAC and [11C]NMSP. Uptake of [11C]RAC in the contralateral putamen was 105% of uptake in the opposite putamen (P = 0.020). For [11C]NMSP, uptake in the contralateral putamen was 105% of uptake in the ipsilateral putamen (P = 0.011). No significant differences between Parkinson's disease patients and healthy volunteers were detected in any of the studied brain regions using either [11C]RAC or [11C]NMSP. No significant differences between [11C]RAC and [11C]NMSP uptake were detected in the striatum, whereas in the extrastriatal regions, [11C]NMSP showed significantly higher uptake than [11C]RAC both in healthy volunteers and in Parkinson's disease patients. CONCLUSION: This study confirms an increase in dopamine D2 receptors in the putamen contralateral to the predominant symptoms, compared with the ipsilateral putamen, in early Parkinson's disease. This increase was seen both with reversible ligand [11C]RAC and with irreversible ligand [11C]NMSP and thus does not seem a consequence of depleted endogenous dopamine.


Subject(s)
Dopamine Agonists , Dopamine Antagonists , Parkinson Disease/diagnostic imaging , Putamen/diagnostic imaging , Raclopride , Receptors, Dopamine D2/metabolism , Spiperone/analogs & derivatives , Tomography, Emission-Computed , Carbon Radioisotopes , Female , Humans , Male , Middle Aged , Parkinson Disease/metabolism , Putamen/metabolism , Up-Regulation/physiology
12.
J Nucl Med ; 41(12): 1980-8, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11138682

ABSTRACT

UNLABELLED: Accurate staging is elementary for optimal management of malignant lymphoma. Advanced cases may be curable with multidrug chemotherapy combined with radiotherapy, whereas limited disease can sometimes be cured by local radiotherapy only. Recently, FDG imaging with whole-body PET (WB PET) has been introduced as an accurate method for staging lymphoma. We evaluated the usefulness of L-[methyl-11C]methionine (MET) in comparison with FDG as a tracer for nodal staging of lymphoma with WB PET. METHODS: Nineteen patients with untreated, histologically proven malignant lymphoma underwent WB PET imaging with MET and FDG within 1 wk before treatment. Fourteen patients had non-Hodgkin's lymphoma (NHL), and 5 had Hodgkin's disease (HD). Two of these 19 patients were excluded from the final analysis because of hyperglycemia. WB PET images using FDG and MET were visually compared by 3 independent interpreters, and the PET findings were correlated with the data on the basis of conventional staging studies. RESULTS: Fifty-five of 178 lymph node regions were classified as diseased both by FDG PET and by CT, and 54 of 178 were classified as diseased both by MET PET and by CT. In addition, 11 lymph node regions that CT showed to be normal avidly accumulated FDG. Ten of these lymph node regions also had clear uptake of MET. Another 4 and 5 lymph node regions were enlarged at CT but were judged to be normal by FDG and MET PET, respectively. In nodal staging, both FDG PET and MET PET would have upstaged the disease in 3 patients. MET PET would also have downstaged the disease in 1 patient. CONCLUSION: FDG and MET seem to be comparable in the detection of lymphoma by WB PET. However, visual interpretation of the images tends to be hampered more by physiologic accumulations of MET than by normal accumulations of FDG, and MET may be preferable to FDG in hyperglycemic patients undergoing staging studies with PET.


Subject(s)
Carbon Radioisotopes , Fluorodeoxyglucose F18 , Lymph Nodes/diagnostic imaging , Lymphoma/diagnostic imaging , Methionine/analogs & derivatives , Radiopharmaceuticals , Tomography, Emission-Computed , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Neoplasm Staging , Tomography, X-Ray Computed
13.
Radiother Oncol ; 52(3): 225-32, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10580868

ABSTRACT

PURPOSE: To evaluate whether positron emission tomography (PET) with carbon-11-methionine (MET) can be used for detection of early response to external beam radiotherapy (RT) in untreated head and neck cancer using locoregional control and survival as study endpoints. MATERIALS: Fifteen patients with head and neck cancer underwent a MET PET study before RT and after a median dose of 24 Gy. Fractionation was standard (n = 6) or hyperfractionated (n = 9), and 13 out of 15 patients had planned surgery after RT. SUV was calculated for primary tumor (n = 13) or largest lymph node metastasis in two patients of whom one had his primary excised before study enrollment and one presented with unknown primary tumor syndrome. METHODS: Attenuation corrected PET scans acquired 20-40 min from tracer injection were used for evaluation of MET uptake in tumors. A quantitative MET uptake index was expressed as standardized uptake value (SUV) or SUV(lean) (corrected for lean body mass). The PET results were correlated with clinical follow-up data. The median follow-up time is currently 28 months (range 22-34). RESULTS: A total of 13 primary tumors and 12 metastatic lymph nodes were visually identified in MET PET. In the first PET study the median SUV in tumor was 8.6 (range, 5.5-14.0). In the second PET study performed during RT the median SUV decreased to 5.7 (range, 3.1-8.2, P = 0.001). Two out of 15 patients showed no radiation-induced decrease in SUV. The median tumor SUV ratio of patients remaining in local control (CR) after RT was 0.7 (range 0.6-0.8, n = 6), and that of relapsing patients similarly 0.7 (range 0.5-1.0, n = 9, NS). The SUV ratio was not associated with survival time. The MET uptake of submandibular salivary glands decreased in all patients during the first two or three weeks of RT (P = 0.03). CONCLUSIONS: MET uptake in tumor shows a significant decrease during the first two to three weeks of RT of head and neck cancer. It appears that the rate of decrease in tracer uptake is comparable in relapsing patients and those who remain locally controlled and thus the use of MET PET for prediction of response to RT is limited.


Subject(s)
Carbon Radioisotopes , Head and Neck Neoplasms/radiotherapy , Methionine , Radiopharmaceuticals , Tomography, Emission-Computed , Aged , Dose Fractionation, Radiation , Evaluation Studies as Topic , Female , Follow-Up Studies , Forecasting , Head and Neck Neoplasms/diagnostic imaging , Head and Neck Neoplasms/surgery , Humans , Lymphatic Metastasis/diagnostic imaging , Male , Middle Aged , Neoplasm Recurrence, Local/prevention & control , Neoplasms, Unknown Primary/pathology , Radiotherapy Dosage , Remission Induction , Submandibular Gland/diagnostic imaging , Survival Rate
14.
Am J Cardiol ; 84(5): 568-74, 1999 Sep 01.
Article in English | MEDLINE | ID: mdl-10482157

ABSTRACT

The integrative mechanisms of autonomic dysfunction in congestive heart failure (CHF) remain poorly understood. We sought to study cardiac retention of [11C]hydroxyephedrine (HED), a specific tracer for sympathetic presynaptic innervation, and its functional correlates in CHF. Thirty patients with mild to moderate heart failure underwent resting cardiac HED positron emission tomography imaging, spectrum analysis testing of systolic pressure and heart rate variability in the resting supine and 70 degrees head-up tilt positions, and testing of baroreflex sensitivity. Compared with control subjects, global myocardial HED retention index was reduced by 30% (p <0.01) in patients with CHF. The HED retention index did not correlate significantly with heart rate variability. However, it correlated with baroreflex sensitivity at rest (r = 0.43, p = 0.05) and with systolic pressure low-frequency (0.03 to 0.15 Hz) variability at head-up tilt (r = 0.76, p <0.01), as well as with low-frequency systolic pressure variability response from baseline to tilt (r = 0.75, p <0.01). We conclude that cardiac HED retention is reduced in patients with CHF. This correlates with blunted vascular sympathetic effector responses during posture-induced reflex activation and baroreflex control of heart rate, suggesting an interdependence between cardiac presynaptic innervation abnormalities and neural mechanisms important to blood pressure maintenance in CHF.


Subject(s)
Ephedrine/analogs & derivatives , Heart Failure/diagnostic imaging , Heart/innervation , Norepinephrine/analogs & derivatives , Sympathetic Nervous System/diagnostic imaging , Sympathomimetics , Tomography, Emission-Computed , Blood Pressure/physiology , Carbon Radioisotopes , Coronary Circulation/physiology , Female , Heart/diagnostic imaging , Heart Failure/physiopathology , Heart Rate/physiology , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Nerve Endings/diagnostic imaging , Nerve Endings/physiopathology , Pressoreceptors/physiopathology , Reference Values , Reflex/physiology , Sympathetic Nervous System/physiopathology
15.
J Cereb Blood Flow Metab ; 19(2): 210-7, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10027776

ABSTRACT

Subacute and long-term stability of measurements of D2 dopamine receptor density (Bmax), affinity (Kd) was studied with positron emission tomography in eight healthy male volunteers. [11C]-Raclopride and the transient equilibrium method were used to measure D2 receptor characteristics. The interval between measurements (scan pairs) was 3 to 7 weeks (subacute) for four subjects and 6 to 11 months (long-term) for four subjects. A test-retest analysis of quantitative measurements of D2 receptor Bmax and Kd was compared with that done on binding potential (BP, Bmax/Kd) measures. In addition, the effect of error in defining the transient equilibrium time (tmax) in the parameter estimation procedure was explored with simulations. The subacute test-retest indicates good reproducibility of D2 receptor density, affinity, and BP ratio measurements with intraclass correlation coefficients of 0.90, 0.96, and 0.86, respectively. The variability of the measurements after 6 to 11 months was slightly higher than that seen in a subacute testing for Kd and more clearly so for binding potential and Bmax. The absolute variability in Bmax (14.5%) measurements was consistently higher than that of Kd (8.4%) or BP (7.9%) both in subacute and long-term measurements. Simulations indicated that the Bmax and Kd estimation procedure is more sensitive to error in the tmax than that for the BP. The results indicate a good overall stability of the equilibrium method with [11C]raclopride for measuring dopamine D2 receptor binding characteristics in the striatum. The BP approach is more stable than Kd and especially Bmax measurements. Error in defining the tmax in particular in the low specific radioactivity scan may be one source of greater variability in Bmax versus BP. However, a higher intraindividual variability in measurements of the D2 receptor Bmax also may include a component of continuous regulation of this parameter over time. These methodologic aspects should be considered in the design and interpretation of longitudinal studies on D2 dopamine receptor characteristics with [11C]-raclopride.


Subject(s)
Corpus Striatum/metabolism , Dopamine Antagonists/metabolism , Receptors, Dopamine D2/metabolism , Salicylamides/metabolism , Adult , Binding, Competitive , Carbon Radioisotopes , Corpus Striatum/diagnostic imaging , Humans , Longitudinal Studies , Male , Raclopride , Reproducibility of Results , Tomography, Emission-Computed
16.
Mol Psychiatry ; 3(3): 256-60, 1998 May.
Article in English | MEDLINE | ID: mdl-9672901

ABSTRACT

Positron emission tomography (PET) studies have revealed significant interindividual variation in dopamine D2 receptor density in vivo in human striatum. Low D2 receptor binding in vivo has been found to associate with alcohol/substance dependence. It has been suggested that the A1 allele of human D2 receptor gene might be associated to a specific type of alcoholism and possibly to a reduced D2 receptor density in vitro. We have determined D2 dopamine receptor-binding density (Bmax), affinity (Kd) and availability (Bmax/Kd) in 54 healthy Finnish volunteers using PET and [11C]raclopride in order to determine whether the A1 allele is associated with a 'baseline' difference in D2 receptor characteristics in vivo. A statistically significant reduction in D2 receptor availability reflecting an alteration in receptor density was observed in the A1/A2 genotype group compared to the A2/A2 group. There was no difference in apparent Kd between the two groups. In conclusion, the association between the A1 allele and low D2 receptor availability in healthy subjects indicates that the A1 allele of the TaqIA polymorphism might be in linkage disequilibrium with a mutation in the promoter/regulatory gene element that affects dopamine D2 receptor expression. This study provides an in vivo neurobiological correlate to the A1 allele in healthy volunteers.


Subject(s)
Brain Chemistry/genetics , Polymorphism, Restriction Fragment Length , Receptors, Dopamine D2/genetics , Adult , Alleles , Brain/diagnostic imaging , Dopamine Antagonists , Dopamine D2 Receptor Antagonists , Female , Finland , Genotype , Humans , Male , Middle Aged , Raclopride , Radioligand Assay , Salicylamides , Tomography, Emission-Computed
17.
Neurology ; 50(1): 152-6, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9443472

ABSTRACT

Striatal dopamine reuptake sites were studied with PET in Alzheimer's disease (AD). A cocaine analogue, [11C]beta-CFT was used as a radioligand. In patients with AD, the reduction in [11C]beta-CFT uptake was about 20% from the age-adjusted mean value in control subjects, both in the putamen (p = 0.002) and in the caudate nucleus (p = 0.002). Thus, the putamen and the caudate nucleus were equally affected, in contrast to Parkinson's disease, which shows predominantly putaminal reduction. We found that the smaller the [11C]beta-CFT uptake in the putamen or in the caudate nucleus, the more severe the extrapyramidal symptoms. In healthy volunteers (nine women, six men; aged 23 to 70 years), [11C]beta-CFT uptake was reduced with age, both in the putamen (r = -0.70, p < 0.01) and in the caudate nucleus (r = -0.77, p < 0.001). The average decline per decade was 4.4% in the putamen and 4.7% in the caudate nucleus. We conclude that the brain dopaminergic system is affected in AD because the striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is decreased. This reduction in [11C]beta-CFT uptake correlates with the severity of the extrapyramidal symptoms of the patients.


Subject(s)
Alzheimer Disease/metabolism , Cocaine/analogs & derivatives , Corpus Striatum/metabolism , Dopamine Uptake Inhibitors/pharmacokinetics , Dopamine/metabolism , Age Factors , Aged , Alzheimer Disease/diagnostic imaging , Carbon Radioisotopes , Cocaine/pharmacokinetics , Corpus Striatum/diagnostic imaging , Female , Humans , Ligands , Male , Middle Aged , Tomography, Emission-Computed
18.
Psychopharmacology (Berl) ; 132(4): 361-5, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9298513

ABSTRACT

Lorazepam is a widely used benzodiazepine class anxiolytic drug. It is known to enhance GABAergic neurotransmission in the brain, but the actions of benzodiazepines on other neurotransmitter systems are largely unknown. We studied the effects of 1 week's administration with lorazepam (2 mg daily, PO) or placebo on striatal D2 dopamine receptors in four healthy male volunteers using a double-blind randomized cross-over design. D2 receptor density and affinity as well as binding potential (Bmax/Kd) were measured with [11C]-raclopride and positron emission tomography. Although the individual responses varied, lorazepam did not significantly affect D2 receptor binding characteristics, nor did the average effect sizes exceed test-retest variability of the method. In conclusion, the results suggest that striatal D2 dopamine receptor characteristics are not affected by the clinically relevant lorazepam treatment regimen used.


Subject(s)
GABA Modulators/pharmacology , Lorazepam/pharmacology , Neostriatum/drug effects , Receptors, Dopamine D2/drug effects , Adult , Carbon Radioisotopes , Cross-Over Studies , Double-Blind Method , Humans , Male , Neostriatum/metabolism , Raclopride , Receptors, Dopamine D2/metabolism , Salicylamides/metabolism , Tomography, Emission-Computed
19.
Clin Pharmacol Ther ; 61(5): 596-607, 1997 May.
Article in English | MEDLINE | ID: mdl-9164421

ABSTRACT

Dynamic positron emission tomography (PET) with [11C]acetate allows noninvasive assessment of myocardial oxygen consumption. In combination with echocardiography, PET enables determination of cardiac efficiency (defined as useful cardiac work per unit of oxygen consumption). We used this approach to compare the effects of levosimendan, a Ca(2+)-dependent calcium sensitizer, with dobutamine and sodium nitroprusside in healthy male volunteers. The effects of levosimendan on k(mono), an index of oxygen consumption, and cardiac efficiency were neutral, whereas the hemodynamic profile was consistent with balanced inotropism and vasodilatation. Dobutamine enhanced cardiac efficiency at the expense of increased oxygen requirement, but the effects of nitroprusside on k(mono) and cardiac efficiency were neutral. This study shows the feasibility of PET in phase 1 pharmacodynamic studies and suggests potential energetical advantages of calcium sensitization with levosimendan.


Subject(s)
Calcium/metabolism , Cardiotonic Agents/pharmacology , Heart/drug effects , Hydrazones/pharmacology , Myocardium/metabolism , Pyridazines/pharmacology , Adult , Carbon Radioisotopes , Cardiotonic Agents/administration & dosage , Chromatography, High Pressure Liquid , Dobutamine/administration & dosage , Dobutamine/pharmacology , Echocardiography , Epinephrine/blood , Feasibility Studies , Hemodynamics/drug effects , Humans , Hydrazones/administration & dosage , Male , Myocardial Contraction/drug effects , Nitroprusside/administration & dosage , Nitroprusside/pharmacology , Norepinephrine/blood , Oxygen Consumption/drug effects , Pyridazines/administration & dosage , Simendan , Sympathomimetics/administration & dosage , Sympathomimetics/pharmacology , Tomography, Emission-Computed , Vasodilation/drug effects , Vasodilator Agents/administration & dosage , Vasodilator Agents/pharmacology
20.
J Nucl Med ; 38(12): 1967-70, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9430478

ABSTRACT

UNLABELLED: The anabolic effects of insulin are not restricted to carbohydrate and lipid metabolism but also include protein metabolism. However, the effects of insulin on protein metabolism have been difficult to demonstrate in vivo. Amino acid transport is partly regulated by insulin according to the experimental data. PET provides a way to measure fractional uptake rates of amino acids. The purpose of this study was to measure the effect of insulin on amino acid transport from the plasma to the human parotid glands. METHODS: We compared the uptake of L-[methyl-11C]methionine ([11C]methionine) into the parotid glands and cerebellum in seven healthy volunteers during the fasting state and euglycemic insulin clamp technique (1 mU/kg per minute). RESULTS: The fractional uptake rate of [11C]methionine was increased by 31% for the right parotid gland (p = 0.003) and by 29% for the left parotid gland (p = 0.009) during insulin clamp, while the increase was 19% for the cerebellum (p = 0.01). The concentration of amino acids typical for the hormone-sensitive transport system A was 11% lower during insulin infusion than in the fasting state. CONCLUSION: The uptake of methionine into brain tissue does not seem to be under major control by insulin, while the transport of methionine in the parotid glands is stimulated by insulin. PET provides a sophisticated method to study the transport system of amino acids in vivo.


Subject(s)
Cerebellum/diagnostic imaging , Insulin/physiology , Methionine/pharmacokinetics , Parotid Gland/diagnostic imaging , Tomography, Emission-Computed , Adult , Amino Acids/blood , Biological Transport , Cerebellum/metabolism , Female , Glucose Clamp Technique , Humans , Male , Middle Aged , Parotid Gland/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...